Isopentyl caffeate as a promising drug for the treatment of leishmaniasis: An in silico and in vivo study

Leishmaniasis is recognised as the second largest parasitic disease worldwide and yet a neglected disease. The current pharmacological treatments are associated with significant challenges, including high toxicity, high cost and parasitic resistance. Considering the potential of isopentyl caffeate (...

Descripción completa

Detalles Bibliográficos

Autores principales:	Wanessa S. Mota, Simone S.C. Oliveira, Matheus M. Pereira, Damião P. Souza, Mayara Castro, Pollyanna S. Gomes, Herbert L.M. Guedes, Vinícius F. Souza, André L.S. Santos, Ricardo L.C. Albuquerque-Junior, Juliana C. Cardoso, Cristina Blanco-Llamero, Sona Jain, Eliana B. Souto, Patrícia Severino
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Elsevier 2024-01-01
Colección:	Current Research in Biotechnology
Materias:	Leishmania Isopentyl caffeate In silico Pharmacokinetics ADME Bioavailability
Acceso en línea:	http://www.sciencedirect.com/science/article/pii/S2590262824000352
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!